Immediate adverse events to intravenous immunoglobulin in pediatric patients with inborn errors of immunity: A longitudinal study with a pre-infusion protocol.

ABSTRACT:

Introduction

Immunoglobulin represents the main therapy for patients with inborn errors of immunity (IEI) and it is a safe procedure, but adverse events (AEs) can occur with variable frequencies.

Objective

To evaluate the frequency of immediate AEs to intravenous immunoglobulin (IVIG) regular therapy in a pediatric cohort with IEI after a pre-IVIG infusion protocol.

Methods

This was a longitudinal study from 2011 to 2019 at a tertiary pediatric hospital in Brazil.

Results

A total of 1736 infusions were studied in 70 patients with IEI, 46 (65.7%) of whom were males and whose median age was 5.8 years old (range: 6 mo - 18 yo). Seven different brands of IVIG were used with the median loading dose of 0.57g/kg (range: 0.23 - 0.88g/Kg). According to the protocol, pre

SUBMITTER: Antunes TS 

PROVIDER: S-EPMC10244234 | biostudies-literature | 2023 Apr-Jun

REPOSITORIES: biostudies-literature